Literature DB >> 24625802

Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

Magdalena Korecka1, Teresa Waligorska1, Michal Figurski1, Jon B Toledo2, Steven E Arnold3, Murray Grossman4, John Q Trojanowski2, Leslie M Shaw2.   

Abstract

The primary aims of this work were to: 1) establish a calibrator surrogate matrix for quantification of amyloid-β (Aβ)42 in human cerebrospinal fluid (CSF) and preparation of quality control samples for LC-MS-MS methodology, 2) validate analytical performance of the assay, and 3) evaluate its diagnostic utility and compare it with the AlzBio3 immunoassay. The analytical methodology was based on a 2D-UPLC-MS-MS platform. Sample pretreatment used 5 M guanidine hydrochloride and extraction on μElution SPE columns as previously described. A column cleaning procedure involved gradual removal of aqueous solvents by acetonitrile assured consistent long-term chromatography performance. Receiver-operator characteristic (ROC) curve and correlation analyses evaluated the diagnostic utility of UPLC-MS-MS compared to AlzBio3 immunoassay for detection of Alzheimer's disease (AD). The surrogate matrix, artificial CSF containing 4 mg/mL of BSA, provides linear and reproducible calibration comparable to human pooled CSF as calibration matrix. Appropriate cleaning of the trapping and analytical columns provided every-day, trouble-free runs. Analyses of CSF Aβ42 showed that UPLC-MS-MS distinguished neuropathologically-diagnosed AD subjects from healthy controls with at least equivalent diagnostic utility to AlzBio3. Comparison of ROC curves for these two assays showed no statistically significant difference (p = 0.2229). Linear regression analysis of Aβ42 concentrations measured by this mass spectrometry-based method compared to the AlzBio3 immunoassay showed significantly higher but highly correlated results. In conclusion, the newly established surrogate matrix for 2D-UPLC-MS-MS measurement of Aβ42 provides selective, reproducible, and accurate results. The documented analytical performance and diagnostic performance for AD versus controls supports consideration as a candidate reference method.

Entities:  

Keywords:  Alzheimer's disease; amyloid-$\beta_{42}$; cerebrospinal fluid; mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 24625802      PMCID: PMC4159707          DOI: 10.3233/JAD-132489

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

Review 1.  Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Authors:  Richard A Frank; Douglas Galasko; Harald Hampel; John Hardy; Mony J de Leon; Pankaj D Mehta; Joseph Rogers; Eric Siemers; John Q Trojanowski
Journal:  Neurobiol Aging       Date:  2003 Jul-Aug       Impact factor: 4.673

Review 2.  Ion suppression in mass spectrometry.

Authors:  Thomas M Annesley
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

Review 3.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

4.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Mary E Lame; Erin E Chambers; Matthew Blatnik
Journal:  Anal Biochem       Date:  2011-08-12       Impact factor: 3.365

5.  Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Authors:  Anne M Fagan; Leslie M Shaw; Chengjie Xiong; Hugo Vanderstichele; Mark A Mintun; John Q Trojanowski; Els Coart; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2011-05-09

6.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 8.  Biomarkers for early detection of Alzheimer pathology.

Authors:  C M Clark; C Davatzikos; A Borthakur; A Newberg; S Leight; V M-Y Lee; J Q Trojanowski
Journal:  Neurosignals       Date:  2007-12-05

9.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.

Authors:  Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-24       Impact factor: 21.566

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  31 in total

Review 1.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

Review 2.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

Review 3.  Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice.

Authors:  Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski
Journal:  J Appl Lab Med       Date:  2020-01-01

4.  Biomarkers of Alzheimer Disease.

Authors:  Melissa M Budelier; Randall J Bateman
Journal:  J Appl Lab Med       Date:  2020-01-01

Review 5.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

6.  Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.

Authors:  Gwënaël Pottiez; Li Yang; Tessandra Stewart; Ning Song; Patrick Aro; Douglas R Galasko; Joseph F Quinn; Elaine R Peskind; Min Shi; Jing Zhang
Journal:  J Proteome Res       Date:  2017-02-07       Impact factor: 4.466

7.  Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Authors:  Niklas Mattsson; Philip S Insel; Michael Donohue; Susan Landau; William J Jagust; Leslie M Shaw; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow; Michael W Weiner
Journal:  Brain       Date:  2014-12-24       Impact factor: 13.501

Review 8.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

Review 9.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2016-12-05       Impact factor: 21.566

10.  Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.

Authors:  B Vellas; R Bateman; K Blennow; G Frisoni; K Johnson; R Katz; J Langbaum; D Marson; R Sperling; A Wessels; S Salloway; R Doody; P Aisen
Journal:  J Prev Alzheimers Dis       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.